|White Blood Cell Growth Factors "Notification"
||Updated "When Covered" section with the following requirements for Neulasta/Neulasta OnPro and Neupogen requests: "the patient has a documented life-threatening side effect that required medical intervention to a biosimilar pegfilgrastim or filgrastim product that is not anticipated with its originator product, Neulasta/Neulasta OnPro or Neupogen; AND the prescriber has completed and submitted an FDA MedWatch Adverse Event Reporting Form (the prescriber must provide a copy of the completed MedWatch form. Authorizations will not be considered unless the form is completed and submitted to the FDA)." Specialty Matched Consultant Advisory Panel review 4/15/2020. Medical Director review 4/2020. Notification given 4/28/2020 for effective date 7/1/2020.